Use of negative pressure in disease treatment, anti-aging, skin function promotion or beauty

Abstract

According to the present invention, there is provided use of a device for applying whole-body negative pressure to a subject in the manufacture of equipment for use in disease treatment, anti-aging, promotion of skin function, and / or non-therapeutic cosmetics. There is also provided a method for disease treatment, anti-aging, promotion of skin function, and / or non-therapeutic cosmetics on a subject, which comprises applying whole-body negative pressure to the subject.

Description

[Technical Field]

[0001] The present invention relates to the field of medical equipment, more particularly to the use of negative pressure in disease treatment, anti-aging, skin function promotion or beauty, and to a negative pressure cabin equipped with an oxygen transport device and its use. [Background technology]

[0002] Cupping, also known as cupping therapy or suction cup therapy, is a traditional Chinese medicine treatment method. It uses a cup as a container, and utilizes the heat of combustion to expel air from inside the cup, generating negative pressure, which is then attached to the skin, causing congestion in the skin at the cupping site, creating a sterile injury-inflammatory response in the body and stimulating the body's immune response, thereby achieving the goal of treating illness. However, it is not recommended for use on areas with high fever, epilepsy, convulsions, or other conditions, skin allergies or ulcers, thin muscles, irregular bone structure, or excessive hair.

[0003] A hypobaric, hypoxic cabin is a device that maintains a lower air pressure inside the cabin than outside. Because of its excellent isolation properties, it is commonly used to isolate infectious patients, preventing the virus from spreading outside the cabin and re-transmitting the virus. According to the Chinese national standard GB / T35428-2017, "Requirements for Environmental Control of Negative-Pressure Isolation Rooms in Hospitals," the negative pressure inside a negative-pressure cabin generally does not exceed -20 Pa relative to the outside air pressure. Commonly available negative-pressure cabins generally generate a negative pressure of no more than -100 Pa relative to the outside air pressure. The negative-pressure, hypoxic environment (<-0.03 MPa) of hypobaric, hypoxic cabins is also commonly used in sports. By adapting athletes to the low-oxygen environment inside the cabin, the oxygen-carrying capacity of red blood cells is improved, thereby improving athletic performance. However, the low-pressure, hypoxic environment in plateau regions makes people more susceptible to plateau reactions due to hypoxia. All research on low-pressure, low-oxygen cabins has focused on the effects of a low-oxygen environment on the human body, and currently no attention has been paid to reporting the effects of the negative pressure environment of a low-pressure, low-oxygen cabin on the human body. Summary of the Invention

[0004] In some embodiments, there is provided the use of a device for providing whole body negative pressure to a subject in the prevention or treatment of disease, anti-aging, life extension, promotion of skin or bodily functions, and / or in the manufacture of cosmetic devices for non-therapeutic purposes.

[0005] In some embodiments, there is provided a use of a device for applying whole-body negative pressure to a subject in the manufacture of equipment for treating disease. In some embodiments, there is provided a use of a device for applying whole-body negative pressure to a subject in the manufacture of equipment for anti-aging. In some embodiments, there is provided a use of a device for applying whole-body negative pressure to a subject in the manufacture of equipment for promoting skin function. In some embodiments, there is provided a use of a device for applying whole-body negative pressure to a subject in the manufacture of equipment for promoting skin function.

[0006] In some embodiments, a method for treating a disease, anti-aging, promoting skin function, and / or non-therapeutic cosmetic treatment is provided for a subject, comprising applying whole-body negative pressure to the subject. In some embodiments, a method for treating a disease is provided for a subject, comprising applying whole-body negative pressure to the subject. In some embodiments, a method for anti-aging is provided for a subject, comprising applying whole-body negative pressure to the subject. In some embodiments, a method for promoting skin function is provided for a subject, comprising applying whole-body negative pressure to the subject. In some embodiments, a non-therapeutic cosmetic treatment is provided for a subject, comprising applying whole-body negative pressure to the subject.

[0007] In some embodiments, a negative pressure cabin is provided, which includes a cabin body, a negative pressure device provided in the cabin body, and an oxygen delivery device provided on or within the cabin body.

[0008] In some embodiments, there is provided a use of a negative pressure cabin in the manufacture of equipment used in disease treatment, anti-aging, skin function promotion, and / or non-therapeutic cosmetics. In some embodiments, there is provided a use of a negative pressure cabin in the manufacture of equipment used in disease treatment. In some embodiments, there is provided a use of a negative pressure cabin in the manufacture of equipment used in anti-aging. In some embodiments, there is provided a use of a negative pressure cabin in the manufacture of equipment used in skin function promotion. In some embodiments, there is provided a use of a negative pressure cabin in the manufacture of equipment used in cosmetics, particularly equipment used in non-therapeutic cosmetics. In some embodiments, there is provided a use of a negative pressure cabin in disease treatment, anti-aging, skin function promotion, and / or non-therapeutic cosmetics. In some embodiments, there is provided a use of a negative pressure cabin in disease treatment. In some embodiments, there is provided a use of a negative pressure cabin in anti-aging. In some embodiments, there is provided a use of a negative pressure cabin in skin function promotion. In some embodiments, there is provided a use of a negative pressure cabin in cosmetics, particularly non-therapeutic cosmetics.

[0009] In some embodiments, a negative pressure cabin is provided for use in disease treatment, anti-aging, skin function promotion and / or non-therapeutic cosmetics. In some embodiments, a negative pressure cabin is provided for use in disease treatment. In some embodiments, a negative pressure cabin is provided for use in anti-aging. In some embodiments, a negative pressure cabin is provided for use in skin function promotion. In some embodiments, a negative pressure cabin is provided for use in skin function promotion. In some embodiments, a negative pressure cabin is provided for use in cosmetics, particularly non-therapeutic cosmetics promotion.

[0010] In some embodiments, the inventors have unexpectedly discovered through research that relatively high negative pressure (>-0.04 MPa, normoxic) conditions can eliminate senescent and damaged cells in vitro without affecting normal young cells. In some embodiments, animal experiments have further discovered that normoxic negative pressure conditions can rejuvenate aged mice and eliminate senescent cells in each tissue, organ, and tissue of aged mice, which is expected to be a new breakthrough in solving aging and related diseases. Therefore, in some embodiments, the present invention uses an innovative oxygen supply design to avoid the adverse effects of hypoxia on the human body and maintain a normoxic negative pressure environment in the human negative pressure cabin, thereby eliminating senescent cells through negative pressure, maintaining the body in a youthful state, and treating aging and related diseases.

[0011] In some embodiments, the disease comprises at least one selected from the group consisting of skin, liver, spleen, brain, kidney, and red blood cell-related diseases.

[0012] In some embodiments, the disease comprises osteoporosis, metabolic inflammation syndrome, heat stress injury, periodontitis, hyperuricemia, depression / anxiety, enteritis, or Alzheimer's disease.

[0013] In some embodiments, the heat stress injury is selected from acute heat stress injury. In some embodiments, the metabolic inflammatory syndrome is selected from obesity, fatty liver, or atherosclerosis. In some embodiments, the fatty liver comprises non-alcoholic fatty liver disease. In some embodiments, the enteritis is selected from colitis.

[0014] In some embodiments, the anti-aging treatment includes preventing or treating aging. In some embodiments, the anti-aging treatment includes reducing the number of senescent cells in a tissue or organ. In some embodiments, the tissue or organ includes at least one selected from the group consisting of the liver, spleen, brain, and kidney. In some embodiments, the promotion of skin or bodily function includes promoting the growth of skin or its appendages. In some embodiments, the promotion of skin or bodily function includes promoting the athletic performance of the subject. In some embodiments, the promotion of the growth of skin or its appendages includes promoting hair regrowth or wound healing.

[0015] In some embodiments, the systemic negative pressure is at least about 0.01 MPa negative relative to atmospheric pressure. In some embodiments, the systemic negative pressure is at least about 0.02 MPa negative relative to atmospheric pressure. In some embodiments, the systemic negative pressure is at least about 0.03 MPa negative relative to atmospheric pressure. In some embodiments, the systemic negative pressure is at least about 0.04 MPa negative relative to atmospheric pressure. In some embodiments, the systemic negative pressure is at least about 0.04 MPa negative relative to atmospheric pressure. In some embodiments, the systemic negative pressure is at least about 0.04 MPa negative relative to atmospheric pressure. In some embodiments, the systemic negative pressure is at least about 0.045 MPa negative relative to atmospheric pressure. In some embodiments, the systemic negative pressure is at least about 0.05 MPa negative relative to atmospheric pressure. In some embodiments, applying whole-body negative pressure to the subject is performed by a device for applying whole-body negative pressure to the subject, wherein the device for applying whole-body negative pressure to the subject has a length of at least about 1 m, optionally between about 1 m and 2 m, optionally between about 1 m and 1.5 m; a width of at least about 1 m, optionally between about 1 m and 2 m, optionally between about 1 m and 1.5 m; a height of at least about 2 m, optionally between about 2 m and 3 m, optionally between about 2 m and 2.5 m; and / or a volume of at least about 1 m. 3 , optionally at least about 2 m 3 , selectively about 2m 3 ~3m 3 is.

[0016] In some embodiments, the percentage of oxygen in the air at the whole-body negative pressure is equal to or greater than the percentage of oxygen in atmospheric air. In some embodiments, the percentage of oxygen in the air at the whole-body negative pressure is at least about 22%. In some embodiments, the percentage of oxygen in the air at the whole-body negative pressure is at least about 25%. In some embodiments, the percentage of oxygen in the air at the whole-body negative pressure is at least about 30%.

[0017] In some embodiments, applying whole-body negative pressure to the subject occurs simultaneously with providing air to the subject's respiratory system having an oxygen percentage equal to or greater than the oxygen percentage of atmospheric air. In some embodiments, the oxygen percentage of the provided air is at least about 22%. In some embodiments, the oxygen percentage of the provided air is at least about 25%. In some embodiments, the oxygen percentage of the provided air is at least about 30%. In some embodiments, the device is a negative pressure cabin.

[0018] In some embodiments, the negative pressure cabin includes a cabin body having a size sufficient to accommodate the entire subject, a negative pressure device provided in the cabin body and capable of lowering the air pressure inside the cabin of the cabin body by at least approximately 0.01 MPa compared to the air pressure outside the cabin of the cabin body, and an oxygen transport device provided on or within the cabin of the cabin body and capable of increasing the ratio of oxygen to air in the space adjacent to the subject's respiratory system inside the cabin of the cabin body to equal or exceed the ratio of oxygen to air outside the cabin of the cabin body.

[0019] In some embodiments, the present invention provides a negative pressure cabin for providing negative pressure to a subject, the negative pressure cabin including: a cabin body having a size capable of accommodating the entire subject; a negative pressure device provided in the cabin body and capable of lowering the air pressure inside the cabin of the cabin body by at least approximately 0.01 MPa below the air pressure outside the cabin of the cabin body; and an oxygen transport device provided on or within the cabin of the cabin body and capable of making the ratio of oxygen to air in a space adjacent to the subject's respiratory system inside the cabin of the cabin body equal to or greater than the ratio of oxygen to air outside the cabin of the cabin body.

[0020] In some embodiments, the negative pressure device can lower the air pressure inside the cabin of the cabin body below the air pressure outside the cabin of the cabin body. The whole-body negative pressure is at least about 0.02 MPa below atmospheric pressure. In some embodiments, the negative pressure device can lower the air pressure inside the cabin of the cabin body below the air pressure outside the cabin of the cabin body. The whole-body negative pressure is at least about 0.03 MPa below atmospheric pressure. In some embodiments, the negative pressure device can lower the air pressure inside the cabin of the cabin body below the air pressure outside the cabin of the cabin body. The whole-body negative pressure is at least about 0.04 MPa below atmospheric pressure. In some embodiments, the negative pressure device can lower the air pressure inside the cabin of the cabin body below the air pressure outside the cabin of the cabin body by at least about 0.04 MPa to 0.06 MPa. In some embodiments, the negative pressure device can lower the air pressure inside the cabin of the cabin body below the air pressure outside the cabin of the cabin body by at least about 0.045 MPa to 0.055 MPa. In some embodiments, the negative pressure device may also reduce the air pressure inside the cabin of the cabin body by at least about 0.05 MPa below the air pressure outside the cabin of the cabin body.

[0021] In some embodiments, the oxygen delivery device is capable of providing an oxygen percentage in the space within the cabin adjacent to the subject's respiratory system of at least about 22%, optionally at least about 25%, optionally at least about 30%.

[0022] In some embodiments, the length of the cabin body is at least about 1 m, optionally about 1 m to 2 m, optionally about 1 m to 1.5 m. In some embodiments, the width of the cabin body is at least about 1 m, optionally about 1 m to 2 m, optionally about 1 m to 1.5 m. In some embodiments, the height of the cabin body is at least about 2 m, optionally about 2 m to 3 m, optionally about 2 m to 2.5 m, and / or the volume is at least about 1 m. 3 , optionally at least about 2 m 3 , selectively about 2m 3 ~3m 3 is.

[0023] In some embodiments, the negative pressure cabin further includes an oxygen supply device connected to the oxygen transport device and air-pressure communicating with the interior of the cabin body via the oxygen transport device, and / or an oxygen transport port connected to the oxygen transport device and connected to the subject to be used to provide oxygen to the subject.

[0024] In some embodiments, the negative pressure cabin further includes a negative pressure destruction device provided in the cabin body, which, under a first state of the negative pressure destruction device, isolates the inside of the cabin from the outside of the cabin by air pressure and, under a second state of the negative pressure destruction device, connects the inside of the cabin to the outside by air pressure; a see-through structure provided in the cabin body that allows the inside of the cabin to be seen from the outside of the cabin and / or that allows the outside of the cabin to be seen from the inside of the cabin; a display device provided in the cabin body; a lighting device provided in the cabin body that faces into the cabin; and / or a control device provided in the cabin body for controlling at least one of the negative pressure device and the oxygen transport device.

[0025] In some embodiments, the present invention provides the use of said negative pressure cabin in the manufacture of equipment for use in the prevention or treatment of disease, life extension, anti-aging and / or promotion of skin or body functions, or non-therapeutic cosmetics.

[0026] In some embodiments, the disorder is selected from a skin, liver, spleen, brain, kidney, and / or red blood cell-related disorder.

[0027] In some embodiments, the disease comprises osteoporosis, metabolic inflammation syndrome, heat stress injury, periodontitis, hyperuricemia, depression / anxiety, enteritis, or Alzheimer's disease.

[0028] In some embodiments, the heat stress injury is selected from acute heat stress injury. In some embodiments, the metabolic inflammatory syndrome is selected from obesity, fatty liver, or atherosclerosis. In some embodiments, the fatty liver comprises non-alcoholic fatty liver disease. In some embodiments, the anti-aging comprises preventing or treating aging. In some embodiments, the anti-aging comprises reducing the number of senescent cells in a tissue or organ. In some embodiments, the tissue or organ comprises at least one selected from the group consisting of the liver, spleen, brain, and kidney. In some embodiments, the promotion of skin or bodily function comprises promoting the growth of skin or its appendages. In some embodiments, the promotion of skin or bodily function comprises promoting athletic performance in the subject. In some embodiments, the promotion of skin function comprises promoting hair regrowth or wound healing. [Brief explanation of the drawings]

[0029] [Figure 1]1A and 1B show schematic diagrams of a negative pressure cabin according to some embodiments of the present invention. 1C and 1D show structural schematic diagrams of a negative pressure cabin according to some embodiments of the present invention. The symbols in FIGS. 1A-1D are explained as follows: 1: perspective structure; 2: display device; 3: lighting device; 4: control device; 5: oxygen transport device; 6: negative pressure device; 7: negative pressure breaking device; 8: cabin door; 10: cabin body; 11: cabin interior; 12: cabin exterior. [Figure 2] This is a comparison diagram of hair changes in aged mice before and after 7 days of negative pressure treatment. [Figure 3] Figures 3A-3D show the changes in blood test values ​​of aged mice before, during, and after negative pressure treatment. Figure 3A shows the white blood cell content (number of white blood cells per liter of blood), Figure 3B shows the red blood cell content (number of red blood cells per liter of blood), Figure 3C shows the platelet content (number of platelets per liter of blood), and Figure 3D shows the lymphocyte ratio. [Figure 4] This shows the lymphocyte and erythrocyte layers of blood in aged mice before and after 7 days of negative pressure treatment. [Figure 5] FIG. 1 shows microscopic images of smears of blood red cell layers of aged mice before and after negative pressure treatment. [Figure 6] β-galactosidase staining of tissue sections from the liver, kidney, spleen, brain, and lung of aged mice in the control group and the group treated with whole-body negative pressure of -0.05 MPa. [Figure 7] Hematoxylin-eosin staining of liver tissue sections from aged mice in the control group and the -0.05 MPa systemic negative pressure treatment group. [Figure 8] The hair growth status of mice in the control group, local negative pressure group, whole body negative pressure -0.02 MPa treatment group, and whole body negative pressure -0.05 MPa treatment group is shown on days 0 to 7 and 14. [Figure 9] Shown are the skin conditions before and after local negative pressure in the local negative pressure group. [Figure 10]Figures 10A-10D show comparative blood test results for mice in the control group, local negative pressure group, systemic negative pressure treatment group (-0.02 MPa), and systemic negative pressure treatment group (-0.05 MPa) on day 14. Figure 10A shows the white blood cell content, Figure 10B shows the red blood cell content, Figure 10C shows the platelet content, and Figure 10D shows the lymphocyte ratio. [Figure 11] 11A shows the oxygen percentage at different negative pressure values ​​in the negative pressure cabin. FIG. 11B shows the blood oxygen concentration of the human body at different negative pressure values. [Figure 12] Figures 12A and 12B show the time course of β-Gal(+) BMSC removal by negative pressure, and Figures 12C and 12D show the time course of apoptosis rates of young and senescent BMSCs during negative pressure treatment. [Figure 13] The results of osteoporosis treatment in aging mice using negative pressure are shown. Figures 13A, 13B, and 13D show changes in β-Gal(+) cells in peripheral blood mononuclear cells in aging mice after 6 weeks of negative pressure treatment. Figures 13C and 13E show changes in P16-positive cells in peripheral blood mononuclear cells in aging mice after 6 weeks of negative pressure treatment. Figures 13F-13K show MicroCT results of femoral bone recovery and changes in bone parameters in aging mice after 6 weeks of negative pressure treatment. [Figure 14] This shows the change in the life cycle of nematodes due to negative pressure treatment. [Figure 15] This shows how negative pressure treatment affects the motility of nematodes. In the figure, the arrow indicates the location of the nematode. [Figure 16] Figure 16 shows the change in C. elegans lipid storage content due to different negative pressure treatments. Figure 16A shows the change in C. elegans lipid droplet content due to different negative pressure treatments. Figure 16B shows the change in C. elegans triglyceride content due to different negative pressure treatments. [Figure 17] 1 shows the change in survival rate of C. elegans after acute heat stress due to different negative pressure treatments. [Figure 18] 1 shows HE staining of the liver following negative pressure treatment of nonalcoholic fatty liver. [Figure 19] 1 shows liver oil red staining for negative pressure treatment of nonalcoholic fatty liver. [Figure 20]1 shows liver Sirius Red staining in relation to negative pressure treatment of nonalcoholic fatty liver. [Figure 21] 1 shows the NAS score for negative pressure treatment of nonalcoholic fatty liver. [Figure 22] 1 shows plasma ALT content in relation to negative pressure treatment of nonalcoholic fatty liver. [Figure 23] 1 shows plasma and tissue cholesterol content in relation to negative pressure treatment of nonalcoholic fatty liver. [Figure 24] This shows the bone recovery status following negative pressure treatment of mouse periodontitis. [Figure 25] Blood tests of hyperuricemia mice after negative pressure treatment are shown. Figure 25 shows the ratio of lymphocytes (LY), monocytes (MO), and neutrophils (GR). Figure 25B shows the platelet-related index. Figure 25C shows the red blood cell-related index. [Figure 26] Figure 25A shows a schematic diagram of the animal experiment, and Figure 25B shows changes in mouse body weight after negative pressure treatment in hyperuricemia mice. [Figure 27] 1 shows a comparison of activity between hyperuricemia mice and mice subjected to negative pressure treatment. [Figure 28] The following shows tests of indices such as blood uric acid and serum creatinine in hyperuricemia mice after negative pressure treatment. Figure 28A shows a blood uric acid test. Figure 28B shows a serum urea nitrogen (BUN) test. Figure 28C shows a serum creatinine (CRE) test. Figure 28D shows a xanthine oxidase (XOD) test in liver tissue. [Figure 29] 1 shows histological HE staining of the liver and kidney of hyperuricemia mice after negative pressure treatment. [Figure 30] Masson staining of kidney tissue from hyperuricemia mice after negative pressure treatment is shown. [Figure 31] 1 shows immunofluorescence staining of kidney tissues from hyperuricemia mice after negative pressure treatment. [Figure 32] 1 shows changes in the movement routes of LPR mice after negative pressure treatment in the central compartment of the open field. [Figure 33] 1 shows changes in the movement time and number of entries in LPR mice after negative pressure treatment on the open arms of an elevated plus maze. [Figure 34] 1 shows changes in the movement time and number of entries in the open arms of an elevated plus maze in LPR mice before and after the self-treatment and negative pressure treatment. [Figure 35] 1 shows changes in the immobility route of LPR mice after negative pressure treatment in the forced swimming test. [Figure 36] 1 shows the change in immobility time in LPR mice after negative pressure treatment in the forced swimming test. [Figure 37] 1 shows changes in colon length in colitis model mice treated with negative pressure. [Figure 38] 1 shows changes in escape time in APP / PS1 mice after negative pressure treatment in the Morris water maze. [Figure 39] Figures 39A-39C show the results of negative pressure treatment on atherosclerosis. Oil Red O staining, triglyceride (TG), and total cholesterol (T-CHO) levels were measured in atherosclerotic plaques from ApoE- / - mice after negative pressure treatment, respectively. DETAILED DESCRIPTION OF THE INVENTION

[0030] In order to further describe the technical means and effects used by the present invention to achieve the desired objectives, the specific embodiments, structures, features and effects of the present invention will be described in detail below with reference to the drawings and preferred examples.

[0031] Hereinafter, many different examples for realizing different features of the present invention will be provided. Specific embodiments or examples of the present invention will be described below to simplify the present invention. Of course, these are merely examples and are not intended to be limiting. The size, shape, ratio, and position of elements shown in the drawings do not represent the actual size, shape, ratio, and position in the embodiments of the present invention. The dimensions of elements are not limited to the disclosed ranges or values ​​and may depend on manufacturing conditions, device characteristics, or actual needs.

[0032] "Containing" or "comprising" means that a combination (e.g., an apparatus, composition, or method) includes listed elements (e.g., each unit of an apparatus, each component of a composition, or a substantial step of a method), but does not exclude other elements. When defining compositions and methods, "consisting essentially of" means excluding other elements that are significant to the intended combination. Thus, a combination of elements essentially defined herein does not exclude other elements that do not materially affect the recitation of the claims. "Consisting of" means a combination (unit components and substantial method steps) excluding other elements. Embodiments defined by each of these transition terms are within the scope of the present invention.

[0033] As used herein, the phrase "a first feature formed 'on' a second feature" may include an embodiment in which the first feature and the second feature are formed in direct contact with each other, and may further include an embodiment in which an additional feature can be formed between the first feature and the second feature so that the first feature and the second feature do not need to be in direct contact with each other. For simplicity and clarity, various features may be arbitrarily drawn in different proportions. For example, the term "on the cabin" used in this specification does not necessarily mean that the referenced element or component is located above the cabin or away from the direction of gravity, but should be interpreted as the referenced component or component being adjacent to either side of the cabin or fitted into the cabin. The referenced element or component may be in direct contact with the cabin, or may not be in direct contact with the cabin due to the presence of an additional element therebetween.

[0034] For ease of explanation, the present invention uses spatially relative terms such as "lower," "below," "down," "upper," "above," "top," "middle," "top," "bottom," "inside," "outside," "side," etc. to describe the relationship of one element or feature to another element or feature shown in the figures. Spatially relative terms are intended to cover different orientations of use or operation of the device, other than the orientation depicted in the figures. The device may be oriented in other ways (rotated 90 degrees or other orientations), and the spatially relative terms used herein may be interpreted similarly. These spatial terms are merely intended to simplify the description of the present invention and should not be understood to indicate or suggest that the depicted device or element necessarily has a particular orientation, is not intended to be configured or operated in a particular orientation, or limit the present invention. In particular, the term "inside the cabin" used in the present invention is equivalent to "inside the cabin body" or "within the cabin body" and refers to a region, part, or space inside the cabin body. The term "outside the cabin body" used in the present invention is equivalent to "outside the cabin body" or "outside the cabin body" and refers to a region, part, or space outside the cabin, such as the atmosphere.

[0035] As used herein, the term "oxygen ratio" (in a specific space) refers to the ratio of oxygen to all gases in the air in the specific space. For example, the oxygen ratio in atmospheric air is approximately 21% (volume fraction). Unless otherwise specified, the value of oxygen ratio in this specification should be considered as a volume fraction, i.e., the ratio of the volume of oxygen to the volume of all gases in the air in the specific space.

[0036] In some embodiments, the cabin body is divided into an inside and an outside of the cabin, and in particular, the inside and the outside of the cabin are pneumatically connected only through elements on the cabin body. In some embodiments, in a first state, the inside and the outside of the cabin are pneumatically isolated, and in a second state, the inside and the outside of the cabin are pneumatically connected.

[0037] In some embodiments, the negative pressure device is used to provide negative pressure to a subject within the cabin. In some embodiments, the negative pressure is a systemic negative pressure. In some embodiments, the device is used to provide negative pressure to the whole body of a subject within a negative pressure cabin.

[0038] In some embodiments, the subject is an animal, e.g., a vertebrate, further e.g., a mammal. In some embodiments, the subject is a human. In some embodiments, the subject is an adult. In some embodiments, the subject is a child. In some embodiments, the subject is a rat. In some embodiments, the subject is a mouse.

[0039] In some embodiments, the size of the cabin body is such that it can accommodate the entire body of a subject within the cabin. In some embodiments, the length of the cabin body is at least 1 m, particularly 1 m to 2 m, particularly 1 m to 1.5 m. In some embodiments, the width of the cabin body is at least 1 m, particularly 1 m to 2 m, particularly 1 m to 1.5 m. In some embodiments, the height of the cabin body is at least 2 m, particularly 2 m to 3 m, particularly 2 m to 2.5 m. In some embodiments, the volume of the cabin body is at least 1 m. 3 and in particular at least 2 m 3 and especially 2m 3 ~3m 3 is.

[0040] In some embodiments, the negative pressure device can lower the cabin air pressure inside the cabin body below the cabin air pressure outside the cabin body. In some embodiments, the negative pressure device can lower the cabin air pressure inside the cabin body below the cabin air pressure outside the cabin body by at least 0.01 MPa, particularly at least 0.02 MPa, particularly at least 0.03 MPa, particularly at least 0.04 MPa. In some embodiments, the negative pressure device can lower the cabin air pressure inside the cabin body below the cabin air pressure outside the cabin body by 0.04-0.06 MPa, particularly 0.045-0.055 MPa, particularly 0.05 MPa. In some embodiments, the negative pressure device is located on a wall of the cabin body, for example, on the ceiling, floor, and / or side wall of the cabin body. In some embodiments, the negative pressure device is located on a side wall of the cabin body. In some embodiments, the negative pressure device is located on the ceiling of the cabin body. In some embodiments, the negative pressure device is located on the floor of the cabin body. In some embodiments, the negative pressure device includes a vacuum pump. In some embodiments, the negative pressure device is connected to the vacuum pump.

[0041] In some embodiments, the oxygen delivery device can increase the oxygen to air ratio in the space adjacent to the subject's respiratory system within the cabin compared to the oxygen to air ratio outside the cabin (i.e., the atmosphere). In some embodiments, the oxygen delivery device can increase the oxygen ratio in the space adjacent to the subject's respiratory system within the cabin by at least 22%, particularly at least 23%, particularly at least 24%, particularly at least 25%, particularly at least 30%, particularly at least 35%, particularly at least 40%, and particularly at least 50% compared to the oxygen ratio outside the cabin. In some embodiments, the oxygen delivery device can deliver oxygen to the subject within the cabin at an oxygen partial pressure equal to or greater than the oxygen partial pressure within the cabin. In some embodiments, the oxygen delivery device can deliver oxygen to the subject within the cabin at at least 1.2 times, particularly at least 1.5 times, and particularly at least 2 times the oxygen partial pressure within the cabin. In some embodiments, the oxygen delivery device can provide a subject in the cabin with a gas having an oxygen percentage equal to or greater than the oxygen percentage of atmospheric air, particularly a gas having an oxygen percentage greater than 50%, particularly a gas having an oxygen percentage greater than 75%, particularly a gas having an oxygen percentage greater than 95%. In some embodiments, the oxygen delivery device can deliver oxygen to a subject in the cabin at an oxygen partial pressure equal to or greater than the oxygen partial pressure outside the cabin of the cabin body. In some embodiments, the oxygen delivery device delivers gas into the cabin in a first state and does not deliver gas into the cabin in a second state. In some embodiments, the oxygen delivery device delivers oxygen into the cabin in a first state and does not deliver oxygen into the cabin in a second state. In some embodiments, at least a portion of the oxygen delivery device is located within the cabin. In some embodiments, the oxygen delivery device is located on a wall of the cabin body, for example, on the ceiling, floor, and / or side wall of the cabin body. In some embodiments, the oxygen delivery device is located on a side wall of the cabin body. In some embodiments, the oxygen delivery device is located on the ceiling of the cabin body. In some embodiments, the oxygen delivery device is located on the floor of the cabin body. In some embodiments, the oxygen delivery device is located within the cabin.In some embodiments, the negative pressure cabin further comprises an oxygen supply device. In some embodiments, the oxygen supply device is connected to the oxygen delivery device and is in air pressure communication with the cabin interior via the oxygen delivery device. In some embodiments, the oxygen supply device is capable of supplying oxygen to the cabin interior. In some embodiments, the oxygen supply device is a high-pressure oxygen cylinder and / or an oxygen generator, particularly a high-pressure oxygen cylinder. In some embodiments, the negative pressure cabin further comprises an oxygen delivery port. In some embodiments, the oxygen delivery port is connected to the oxygen delivery device to provide oxygen to the subject. In some embodiments, the oxygen delivery port is, for example, an oxygen mask and / or an oxygen tube, particularly an oxygen mask.

[0042] In some embodiments, the oxygen delivery device is connected to an oxygen delivery port. In some embodiments, the oxygen delivery device is connected to an oxygen supply. In some embodiments, the oxygen delivery device includes an oxygen vent tube or oxygen vent. In some embodiments, the oxygen delivery device includes an oxygen vent tube or oxygen vent, which is connected to the oxygen delivery port and to the oxygen supply.

[0043] In some embodiments, the negative pressure cabin further includes a negative pressure break device located in the cabin body. In some embodiments, the negative pressure break device can provide air pressure communication between the inside and outside of the cabin body. In some embodiments, the negative pressure break device provides air pressure communication between the inside and outside of the cabin body in a first state and air pressure isolation between the inside and outside of the cabin body in a second state. In some embodiments, the negative pressure break device makes the air pressure inside the cabin body the same or approximately the same as the air pressure outside the cabin body. In some embodiments, the negative pressure break device includes a valve. In some embodiments, the negative pressure break device is configured to convert the inside and outside of the cabin from air pressure isolation to air pressure communication when there is an air pressure difference between the inside and outside of the cabin, for example, when the air pressure inside the cabin is lower than the air pressure outside the cabin body. In some embodiments, the negative pressure break device is located on a wall of the cabin body, for example, on the ceiling, floor, and / or side wall of the cabin body. In some embodiments, the negative pressure break device is located on a side wall of the cabin body. In some embodiments, the negative pressure break device is located on the ceiling of the cabin body. In some embodiments, the negative pressure break device is located on the floor of the cabin body.

[0044] In some embodiments, the negative pressure cabin further includes a cabin door. In some embodiments, the cabin door is located on a wall of the cabin body, for example, on the ceiling, floor, and / or side wall of the cabin body. In some embodiments, the cabin door is located on a side wall of the cabin body. In some embodiments, the cabin door is located on the ceiling of the cabin body. In some embodiments, the cabin door is located on the floor of the cabin body. In some embodiments, the cabin door is arranged so that in a first state, the inside of the cabin body and the outside of the cabin are pressure-communicated, and in a second state, the inside of the cabin body and the outside of the cabin are pressure-isolated. In some embodiments, the height of the cabin door is at least 0.9 m, particularly 0.9 m to 1.35 m, particularly 0.9 m to 1.2 m. In some embodiments, the height of the cabin door is at least 1.8 m, particularly 1.8 m to 2.7 m, particularly 1.8 m to 2.4 m.

[0045] In some embodiments, the negative pressure cabin further includes a viewing structure. In some embodiments, the viewing structure is located on a wall of the cabin body, for example, on the ceiling, floor, and / or side wall of the cabin body. In some embodiments, the viewing structure is located on a side wall of the cabin body. In some embodiments, the viewing structure is located on the ceiling of the cabin body. In some embodiments, the viewing structure is located on the floor of the cabin body. In some embodiments, the viewing structure includes a transparent material. In some embodiments, the viewing structure allows the interior of the cabin to be seen from the outside. In some embodiments, the viewing structure allows the interior of the cabin to be seen from the inside. In some embodiments, the viewing structure is a window. In some embodiments, the viewing structure is a fixed window.

[0046] In some embodiments, the negative pressure cabin further includes a display device. In some embodiments, the display device is located on a wall of the cabin body, for example, on the ceiling, floor, and / or side wall of the cabin body. In some embodiments, the display device is located on a side wall of the cabin body. In some embodiments, the display device is located on the ceiling of the cabin body. In some embodiments, the display device is located on the floor of the cabin body. In some embodiments, the display device faces into the cabin. In some embodiments, the display device faces outside the cabin. In some embodiments, the negative pressure cabin includes multiple displays. One of the multiple displays faces outside the cabin and one of the multiple displays faces into the cabin. In some embodiments, the display device is a display screen. In some embodiments, the display device is an interactive device, for example, a touch display screen.

[0047] In some embodiments, the negative pressure cabin further includes a lighting device. In some embodiments, the lighting device is located on a wall of the cabin body, for example, on the ceiling, floor, and / or side wall of the cabin body. In some embodiments, the lighting device is located on a side wall of the cabin body. In some embodiments, the lighting device is located on the ceiling of the cabin body. In some embodiments, the lighting device is located on the floor of the cabin body. In some embodiments, the lighting device faces into the cabin. In some embodiments, the lighting device faces outside the cabin. In some embodiments, the negative pressure cabin includes multiple lighting devices, one of the multiple lighting devices facing outside the cabin and one of the multiple lighting devices facing into the cabin.

[0048] In some embodiments, the negative pressure cabin further includes a control device. In some embodiments, the control device is located on a wall of the cabin body, for example, on the ceiling, floor, and / or side wall of the cabin body. In some embodiments, the control device is located on a side wall of the cabin body. In some embodiments, the control device is located on the ceiling of the cabin body. In some embodiments, the control device is located on the floor of the cabin body. In some embodiments, the control device controls at least one selected from a perspective structure, a display device, a lighting device, an oxygen delivery device, an oxygen supply device, an oxygen delivery port, a negative pressure device, a vacuum pump, a negative pressure break device, and a cabin door. In some embodiments, the control device controls the perspective structure. In some embodiments, the control device controls the display device. In some embodiments, the control device controls the lighting device. In some embodiments, the control device controls the oxygen delivery device. In some embodiments, the control device controls the oxygen supply device. In some embodiments, the control device controls the oxygen delivery port. In some embodiments, the control device controls the negative pressure device. In some embodiments, the control device controls the vacuum pump. In some embodiments, the control device controls the negative pressure break device. In some embodiments, the control device controls the cabin door.

[0049] In some embodiments, the disease is selected from or consists of the group consisting of skin, liver, spleen, brain, kidney, and red blood cell related diseases. In some embodiments, the disease is selected from or consists of the group consisting of liver, spleen, brain, and kidney. In some embodiments, the disease is a skin related disease. In some embodiments, the disease is a liver related disease. In some embodiments, the disease is a spleen related disease. In some embodiments, the disease is a brain related disease. In some embodiments, the disease is a kidney related disease. In some embodiments, the disease is an red blood cell related disease.

[0050] In some embodiments, anti-aging comprises reducing the number of senescent cells in a tissue or organ. In some embodiments, the tissue or organ comprises or consists of at least one selected from the group consisting of skin, liver, spleen, brain, kidney, and red blood cells. In some embodiments, the tissue or organ comprises or consists of at least one selected from the group consisting of liver, spleen, brain, and kidney. In some embodiments, the tissue or organ comprises or consists of skin. In some embodiments, the tissue or organ comprises or consists of liver. In some embodiments, the tissue or organ comprises or consists of spleen. In some embodiments, the tissue or organ comprises or consists of brain. In some embodiments, the tissue or organ comprises or consists of kidney. In some embodiments, the tissue or organ comprises or consists of red blood cells. In some embodiments, anti-aging comprises reducing the number of senescent skin cells or the proportion of senescent skin cells in skin cells. In some embodiments, anti-aging comprises reducing the number of senescent hepatocytes or the proportion of senescent hepatocytes in hepatocytes. In some embodiments, anti-aging comprises decreasing the number of senescent spleen cells or the proportion of senescent spleen cells in spleen cells. In some embodiments, anti-aging comprises decreasing the number of senescent brain cells or the proportion of senescent brain cells in brain cells. In some embodiments, anti-aging comprises decreasing the number of senescent kidney cells or the proportion of senescent kidney cells in kidney cells. In some embodiments, anti-aging comprises decreasing the number of senescent red blood cells or the proportion of senescent red blood cells in red blood cells.

[0051] In some embodiments, the systemic negative pressure is at least 0.01 MPa negative relative to atmospheric pressure. In some embodiments, the systemic negative pressure is at least 0.02 MPa negative relative to atmospheric pressure. In some embodiments, the systemic negative pressure is at least 0.03 MPa negative relative to atmospheric pressure. In some embodiments, the systemic negative pressure is at least 0.04 MPa negative relative to atmospheric pressure. In some embodiments, the systemic negative pressure is 0.04 MPa to 0.06 MPa negative relative to atmospheric pressure. In some embodiments, the systemic negative pressure is 0.045 MPa to 0.055 MPa negative relative to atmospheric pressure. In some embodiments, the systemic negative pressure is 0.05 MPa negative relative to atmospheric pressure.

[0052] In some embodiments, applying whole-body negative pressure to a subject is performed by a device for applying whole-body negative pressure to a subject. In some embodiments, the device for applying whole-body negative pressure to a subject has a length of at least 1 m, particularly 1 m to 2 m, particularly 1 m to 1.5 m. In some embodiments, the device for applying whole-body negative pressure to a subject has a width of at least 1 m, particularly 1 m to 2 m, particularly 1 m to 1.5 m. In some embodiments, the device for applying whole-body negative pressure to a subject has a height of at least 2 m, particularly 2 m to 3 m, particularly 2 m to 2.5 m. In some embodiments, the device for applying whole-body negative pressure to a subject has a volume of at least 1 m. 3 , especially at least 2 m 3 , especially 2m 3 ~3m 3 is.

[0053] In some embodiments, the oxygen percentage in the air under whole-body negative pressure is equal to or greater than the oxygen percentage in atmospheric air. In some embodiments, the oxygen percentage in the air under whole-body negative pressure is greater than the oxygen percentage in atmospheric air. In some embodiments, the oxygen percentage in the air under whole-body negative pressure is at least 22%, particularly at least 23%, particularly at least 24%, particularly at least 25%, particularly at least 30%, particularly at least 35%, particularly at least 40%, particularly at least 50%.

[0054] In some embodiments, applying whole-body negative pressure to a subject occurs in the context of providing air to the subject's respiratory system with an oxygen percentage equal to or greater than atmospheric oxygen. In some embodiments, the device for applying whole-body negative pressure to a subject also simultaneously provides air to the subject's respiratory system with an oxygen percentage equal to or greater than atmospheric oxygen. In some embodiments, the subject's disease treatment, anti-aging, skin function promotion, and / or non-therapeutic cosmetic method further comprises providing air to the subject's respiratory system with an oxygen percentage equal to or greater than atmospheric oxygen.

[0055] In some embodiments, the oxygen percentage of the air provided to the subject's respiratory system is at least 22%, particularly at least 23%, particularly at least 24%, particularly at least 25%, particularly at least 30%, particularly at least 35%, particularly at least 40%, particularly at least 50% higher than the oxygen percentage in atmospheric air.

[0056] Through mechanism exploration and experimental confirmation, the inventors found that local negative pressure cannot achieve the same changes in the body's systemic mechanisms as systemic negative pressure. This may be due to the significant difference in the effects of the two on the body's circulatory system (Figure 4, Figures 10A-10D). This may be closely related to the clear difference between the two in ultimately promoting functional improvement of skin-related structures.

[0057] In this specification and drawings, and particularly in the following examples, unless explicitly stated otherwise, the pressure difference expressed in MPa is calculated by subtracting the pressure outside the cabin from the pressure inside the negative pressure cabin. For example, a pressure difference of "-0.05 MPa" means that the pressure inside the cabin is 0.05 MPa lower than the pressure outside the cabin.

[0058] In this specification and drawings, the term "day 0" refers to the time before negative pressure treatment. The term "day n" (n = 1-14) refers to the time after negative pressure treatment, counting from the first negative pressure treatment as day 1, if negative pressure treatment is performed on that day. For example, "day 7" refers to the time after seven days of negative pressure treatment counting from day 1, and "day 14" refers to the seventh day after recovery to a normal rearing environment (without negative pressure treatment) after seven days of negative pressure treatment counting from day 1.

[0059] Unless otherwise specified herein, in Examples 3-15 the oxygen content is 20 kPa-21 kPa.

[0060] In this specification, unless otherwise specified, "topical negative pressure" refers to a 10-minute treatment with a local negative pressure of -0.02 MPa daily for 7 days.

[0061] In the examples herein, unless otherwise specified, the negative pressure treatment of test animals was as follows.

[0062] After the test animals are transferred inside the cabin, the cabin door is closed and negative pressure treatment is carried out. The air pressure during negative pressure treatment is -0.04MPa to -0.06MPa. After negative pressure treatment is complete, the door is opened, the test animals are removed, and then ultraviolet sterilization is carried out. Negative pressure treatment is carried out for two hours every day for seven days.

[0063] Example 1: Negative pressure cabin

[0064] 1A and 1B are schematic diagrams of a negative pressure cabin according to some embodiments of the present invention, and 1C and 1D are structural schematic diagrams of a negative pressure cabin according to some embodiments of the present invention.

[0065] The negative pressure cabin can provide a whole-body negative pressure to a subject. In some embodiments, the negative pressure cabin 100 includes a cabin body 10. The cabin body 10 divides a space into an interior cabin 11 and an exterior cabin 12.

[0066] The negative pressure cabin 100 may include a negative pressure device 6 on the cabin body 10. The negative pressure device 6 may be located on any wall of the cabin body 10, for example, on the ceiling, floor, and / or side wall of the cabin body 10. The negative pressure device 6 may be used to create a pressure difference between the cabin interior 11 and the cabin exterior 12, for example, to make the air pressure inside the cabin 11 lower than the air pressure outside the cabin 12 and / or to make the air pressure inside the cabin 11 lower than atmospheric pressure. In some embodiments, the negative pressure device 6 may be connected to a vacuum pump 61 to draw gas out of the cabin interior 11.

[0067] The negative pressure cabin 100 may include a negative pressure break device 7 on the cabin body 10. The negative pressure break device 7 may be located on any wall of the cabin body 10, for example, on the ceiling, floor, and / or side wall of the cabin body 10. The negative pressure break device 7 can reduce the air pressure difference between the cabin interior 11 and the cabin exterior 12. For example, by pressure-communicating the cabin interior 11 and the cabin exterior 12, the air pressure difference between the cabin interior 11 and the cabin exterior 12 can be reduced to zero or nearly zero, or the air pressures inside the cabin 11 and the cabin exterior 12 can be made the same or nearly the same. In some embodiments, the negative pressure break device 7 may be a valve. By opening the valve, the air pressure difference between the cabin interior 11 and the cabin exterior 12 can be reduced. For example, the air pressure difference between the cabin interior 11 and the cabin exterior 12 can be reduced to zero or nearly zero, or the air pressures inside the cabin 11 and the cabin exterior 12 can be made the same or nearly the same. Closing the valve provides pressure isolation between the inside of the cabin 11 and the outside of the cabin 12. In some embodiments, the negative pressure device 6 and the negative pressure breaker 7 may be the same structure. In some embodiments, the negative pressure device 6 and the negative pressure breaker 7 may be two separate structures.

[0068] The negative pressure cabin 100 may include an oxygen delivery device 5 on the cabin body 10 or in the cabin interior 11. In some embodiments, at least a portion of the oxygen delivery device 5 is located in the cabin interior 11. Specifically, in some embodiments, the oxygen delivery device 5 may be located on any wall of the cabin body 10, such as the ceiling, floor, and / or side wall of the cabin body 10. In some embodiments, the oxygen delivery device 5 is located entirely in the cabin interior 11. The oxygen delivery device 5 can be used to increase the oxygen partial pressure at a specific location in the cabin interior 11, for example, to make the oxygen percentage in the air at the specific location in the cabin interior 11 higher than the oxygen percentage in the air outside the cabin 12 or other locations in the cabin interior 11, for example, to make the oxygen partial pressure at the specific location in the cabin 11 the same as the oxygen partial pressure outside the cabin 12. In some embodiments, the oxygen delivery device 5 may be connected to an oxygen supply device 51. The oxygen supply device 51 is for providing oxygen to the oxygen delivery device 5 so that the oxygen delivery device 5 delivers oxygen to the cabin interior 11.

[0069] In some embodiments, the oxygen delivery device 5 can be connected to an oxygen delivery port 52, e.g., an oxygen mask, and can be used to deliver oxygen to a subject, e.g., to connect to the subject's airway, in the cabin 11. For example, the oxygen percentage in the air adjacent to the subject can be made higher than the oxygen percentage in the air outside the cabin 12 or elsewhere in the cabin 11, e.g., the oxygen partial pressure in the air adjacent to the subject can be made the same as the oxygen partial pressure outside the cabin 12.

[0070] In some embodiments, the negative pressure cabin 100 may include a cabin door 8 on the cabin body 10. The cabin door 8 may be located on any wall of the cabin body 10, for example, on the ceiling, floor, and / or side wall of the cabin body 10. The cabin door 8 is for an object to enter the cabin body 10. In some embodiments, the cabin door 8 may be an airtight door. In some embodiments, when the cabin door 8 is opened, the cabin interior 11 and the cabin exterior 12 are in air pressure communication. In some embodiments, when the cabin door 8 is closed, the cabin interior 11 and the cabin exterior 12 are air pressure isolated, i.e., there is an air pressure difference between the cabin interior 11 and the cabin exterior 12, or it can be said that the cabin interior 11 is isolated from the atmosphere.

[0071] The material and structure of the cabin body 10 and / or the cabin door 8 are not particularly limited, and they only need to be able to withstand the pressure difference between the cabin interior 11 and the cabin exterior 12 created by the negative pressure device 6. The size of the cabin body 10 and / or the cabin door 8 is also not limited, and they only need to accommodate the entire body of the subject to which negative pressure is applied. For example, in some embodiments, when applying negative pressure to a human, the size of the cabin body 10 is set to a size that can accommodate the entire body of a human, for example, a length of 1 m or more, a width of 1 m or more, and / or a height of 2 m or more, for example, a length of 1.5 m or more, a width of 1.5 m or more, and / or a height of 2.5 m or more, and / or a volume of 1 m. 3 The cabin door 8 is for a person to enter the cabin body 10, and may be sized to a size that allows a person to pass through, for example, a width of 0.9 m or more and / or a height of 1.8 m, but is not limited to this.

[0072] In some embodiments, the negative pressure cabin 100 may include a viewing structure 1 on the cabin body 10. In some embodiments, the viewing structure 1 may be located on any wall of the cabin body 10, such as the ceiling, floor and / or side wall, particularly the side wall, of the cabin body 10. In some embodiments, the viewing structure 1 may include a transparent material, such as glass or transparent plastic, which allows an observer outside the cabin 12 to observe the situation inside the cabin 11 and / or allows an observer inside the cabin 11 to observe the situation outside the cabin 12. In some embodiments, the viewing structure 1 may be a window, such as a fixed window.

[0073] In some embodiments, the negative pressure cabin 100 may include a display device 2 in the cabin body 10. In some embodiments, the display device 2 may be located on any wall of the cabin body 10, for example, on the ceiling, floor, and / or side wall, particularly on the side wall, of the cabin body 10. In some embodiments, the display device 2 may be a display screen. In some embodiments, the display device 2 may have interactive functionality. For example, the display device 2 may be a touch display screen. In some embodiments, the display device 2 may display toward the outside of the cabin 12. In some embodiments, the display device 2 may display toward the inside of the cabin 11. In some embodiments, the display device 2 may simultaneously display toward the outside of the cabin 12 and the inside of the cabin 11. In some embodiments, multiple display devices 2 may be included, one or more of which may display toward the outside of the cabin 12 and another of which may display toward the inside of the cabin 11.

[0074] In some embodiments, the negative pressure cabin 100 may include a lighting device 3 in the cabin body 10. The lighting device 3 is for providing illumination to the cabin interior 11. In some embodiments, the lighting device 3 may be provided below the ceiling of the cabin body 10 so as to face the cabin interior 11.

[0075] In some embodiments, the negative pressure cabin 100 may include a control device 4 on the cabin body 10, for example, for controlling one or more of the see-through structure 1, the display device 2, the lighting device 3, the oxygen delivery device 5, the negative pressure device 6, and the negative pressure break device 7. In some embodiments, the control device 4 may be located on any wall of the cabin body 10, for example, on the ceiling, floor, and / or side wall of the cabin body 10, particularly on the side wall. In some embodiments, the control device 4 may be a power switch, for example, for controlling the on / off of one or more of the display device 2, the lighting device 3, the oxygen delivery device 5, the negative pressure device 6, and the negative pressure break device 7. In some embodiments, the control device 4 may be a control device for controlling the lighting device 3, for example, a switch for the lighting device 3. In some embodiments, the control device 4 may be a control device for controlling the display device 2. In some embodiments, the control device 4 may be a control device for controlling the oxygen delivery device 5. In some embodiments, the control device 4 may be a control device for controlling the negative pressure device 6. In some embodiments, the control device 4 may be a control device for controlling the negative pressure break device 7, for example, a switch for the negative pressure break device 7. In some embodiments, the control device 4 may be a control device for controlling the cabin door 8, such as a switch on the cabin door 8. In some embodiments, the control device 4 may be a control device for controlling the perspective structure 1. In some embodiments, the control device 4 may include multiple devices for controlling different elements of the perspective structure 1, the display device 2, the lighting device 3, the oxygen transport device 5, the negative pressure device 6, the negative pressure breaking device 7, and the cabin door 8.

[0076] Example 2: How to use the negative pressure cabin

[0077] In some embodiments, the method of use of the negative pressure cabin 100 is as follows.

[0078] The subject is allowed to enter cabin 11. For example, the subject enters cabin 11 on its own, or the subject is transferred into cabin 11. In some embodiments, the subject may be a human or other animal, such as a rat or mouse. The age and body type of the subject are not particularly limited in the present invention, and the entire subject may be placed inside cabin 11, or the cabin body 10 may be able to accommodate the entire subject.

[0079] The oxygen delivery device 5 is connected to the subject. In some embodiments, an oxygen mask of the oxygen delivery device 5 is connected to the subject's respiratory system. For example, the subject is fitted with an oxygen mask. In some embodiments, the oxygen delivery device 5 may be connected to the subject before the subject enters the cabin 11. In some embodiments, the oxygen delivery device 5 may be connected to the subject after the subject enters the cabin 11.

[0080] After the subject enters cabin 11, cabin door 8 is closed to barometrically isolate cabin 11 from exterior cabin 12, i.e., isolate cabin 11 from the atmosphere. In some embodiments, cabin door 8 may be closed before connecting oxygen delivery device 5 to the subject. In some embodiments, cabin door 8 may be closed after connecting oxygen delivery device 5 to the subject.

[0081] The negative pressure device 6 reduces the air pressure inside the cabin 11 to create a predetermined air pressure difference between the inside of the cabin 11 and the outside of the cabin 12, and maintains the air pressure difference between the inside of the cabin 11 and the outside of the cabin 12, thereby placing the subject in an air pressure environment lower than the air pressure outside the cabin 12. In some embodiments, oxygen may be provided to the subject by the oxygen delivery device 5. In some embodiments, the entire subject is placed in an air pressure environment lower than the air pressure outside the cabin 12.

[0082] The negative pressure breaking device 7 connects the inside of the cabin 11 and the outside of the cabin 12 in air pressure communication, thereby reducing the air pressure difference between the inside of the cabin 11 and the outside of the cabin 12. For example, the air pressure difference between the inside of the cabin 11 and the outside of the cabin 12 is reduced to zero or nearly zero, or the air pressures inside the cabin 11 and the outside of the cabin 12 are made the same or nearly the same.

[0083] The object is allowed to leave the cabin 11. In some embodiments, after the object has left the cabin 11, a subsequent treatment, for example, an ultraviolet disinfection treatment, may be performed.

[0084] Example 3: Comparison of aged mice before and after negative pressure treatment

[0085] 1. Experimental Method

[0086] One-week-old aged C57BL6 mice were used as test animals. The experimental groups included a control group (no negative pressure treatment) and a whole-body negative pressure treatment group (-0.05 MPa whole-body negative pressure treatment group using the negative pressure cabin of the present invention for 2 hours every day at -0.05 MPa for a total of 7 days).

[0087] On days 0 and 7, the test animals in the -0.05 MPa whole-body negative pressure treatment group (using the negative pressure cabin of the present invention, whole-body negative pressure treatment at -0.05 MPa for 2 hours every day for a total of 7 days) were anesthetized with isoflurane, photographed, and the changes in hair before and after the negative pressure were compared.

[0088] On days 0, 1, 3, and 7, the test animals in the -0.05 MPa systemic negative pressure treatment group were anesthetized, blood samples were taken, and blood tests were performed. The lymphocyte and red blood cell layers of the aged mice were separated using mouse lymphocyte separation fluid, and the red blood cells were collected and subjected to smear tests.

[0089] After blood was collected from the control group and the -0.05 MPa systemic negative pressure treatment group on day 7, the animals were euthanized by cervical dislocation. Then, tissues and organs such as the heart, liver, spleen, lungs, kidneys, and brain were separated and fixed with paraformaldehyde. Then, they were dehydrated and embedded in paraffin. 5 μm-thick tissue sections were sliced ​​and stained for senescent cells using β-galactosidase staining. Important organs were stained with hematoxylin-eosin (HE) staining for observation.

[0090] 2. Experimental Results

[0091] (1) Changes in hair of aging mice before and after negative pressure

[0092] Figure 2 is a comparison of hair changes in aged mice before and after 7 days of negative pressure treatment.

[0093] As shown in Figure 2, before the aging mice were subjected to negative pressure for 7 days (day 0), a few white hairs were found in their hair, and partial hair loss and a wound were observed in the center of their backs. After the aging mice were subjected to negative pressure for 7 days (day 7), the hair became thicker, the number of white hairs decreased, the wound in the center of their backs healed, and new hair began to grow.

[0094] (2) Effect of negative pressure treatment on blood tests in aged mice

[0095] Figures 3A-3D show a comparison of changes in blood test values ​​in aged mice before, during, and after negative pressure treatment (days 0, 1, 3, and 7). Figure 3A shows white blood cell content, Figure 3B shows red blood cell content, Figure 3C shows platelet content, and Figure 3D shows lymphocyte ratio.

[0096] As shown in Figures 3A-3D, after negative pressure treatment in aged mice, the white blood cell count decreased, the proportion of lymphocytes to the total white blood cell count increased, the red blood cell count increased after 7 days of negative pressure treatment, and the platelet count increased.

[0097] (3) Effects of negative pressure on lymphocyte and erythrocyte layers in aged mice

[0098] Figure 4 shows the stratification of the blood lymphocyte layer and red blood cell layer of the blood of an aged mouse before and after negative pressure treatment. Figure 5 shows a microscopic image of a smear examination of the blood red blood cell layer of an aged mouse before and after negative pressure treatment.

[0099] As shown in Figure 4, after 7 days of negative pressure treatment in aged mice, lymphocyte differentiation became more obvious, the number of lymphocytes increased, and the red blood cell layer became more numerous. As shown in Figure 5, after 1 day of negative pressure treatment in aged mice, the number of aged red blood cells increased, and after 3 days and 7 days of negative pressure treatment, the number of aged red blood cells decreased.

[0100] (4) Changes in senescent cells in various tissues and organs of aging mice before and after negative pressure treatment

[0101] Figure 6 shows β-galactosidase staining of tissue sections from the liver, kidney, spleen, brain, and lung of aged mice in the control and -0.05 MPa systemic negative pressure treatment groups. Figure 7 shows hematoxylin and eosin staining of tissue sections from the liver, kidney, spleen, brain, and lung of aged mice in the control and -0.05 MPa systemic negative pressure treatment groups.

[0102] As shown in Figure 6, senescent cells (β-gal positive; blue in the figure) were reduced in the liver, kidney, spleen, brain, and lungs of aged mice that underwent negative pressure treatment for 14 days.

[0103] As shown in Figure 7, compared with normal aging mice, liver tissue from aging mice after negative pressure treatment showed a significant reduction in vacuolar degeneration and clearer tubular shapes; spleen tissue showed a decrease in red pulp thickness and an increase in white pulp diameter; brain tissue showed a decrease in perinuclear heterochromatin and a decrease in nuclear volume; and lung tissue showed a decrease in perialveolar inflammatory cells and clearer alveolar structures.

[0104] Example 4: Comparison of young mice before and after negative pressure treatment

[0105] 1. Experimental Method

[0106] Eight-week-old C57BL6 mice were used as test animals.

[0107] After the test animals were anesthetized, the hair on their backs was shaved and treated with a hair removal cream to remove the hair from the backs.

[0108] The test animals were then subjected to negative pressure treatment. The experimental groups included a control group (no negative pressure treatment), a local negative pressure group (locally treated with negative pressure at -0.02 MPa for 10 minutes every day for a total of 7 days), a whole-body negative pressure treatment group (using the negative pressure cabin of the present invention, whole-body negative pressure treatment at -0.02 MPa for 2 hours every day for a total of 7 days), and a whole-body negative pressure treatment group (using the negative pressure cabin of the present invention, whole-body negative pressure treatment at -0.05 MPa for 2 hours every day for a total of 7 days).

[0109] Photographs were taken daily to observe hair growth from day 0 to day 7. After 7 days of negative pressure treatment, the mice were returned to a normal breeding environment and reared for another 7 days. On day 14, photographs were taken to observe hair growth, and the mice were anesthetized and blood samples were taken for blood tests.

[0110] . 2. Experimental Results

[0111] (1) The effect of negative pressure treatment on hair regrowth in mice

[0112] Figure 8 shows the hair growth status of young mice in the control group, local negative pressure group, systemic negative pressure treatment group (-0.02 MPa), and systemic negative pressure treatment group (-0.05 MPa) every day from day 0 to day 7 and on day 14. Figure 9 shows the skin condition of the local negative pressure group before and after local negative pressure (local negative pressure -0.05 MPa, time 10 min).

[0113] As shown in Figure 8, the local negative pressure treatment group at -0.02 MPa did not show a significant hair regrowth promotion effect compared to the control group. The whole-body negative pressure treatment group at -0.02 MPa showed a significant hair regrowth promotion effect when treated for 14 days compared to the local negative pressure treatment group at -0.02 MPa. The whole-body negative pressure treatment group at -0.05 MPa further improved the hair regrowth promotion effect based on the effect obtained in the whole-body negative pressure treatment group at -0.02 MPa.

[0114] The effects of whole-body negative pressure cannot be achieved by local negative pressure. Through mechanism exploration, the inventors discovered that the changes in the body's systemic mechanisms induced by whole-body negative pressure cannot be achieved by local negative pressure. For example, not only are the effects of the two methods on the circulatory system significantly different, but whole-body negative pressure can achieve situations that local negative pressure cannot. For example, experiments have shown that local negative pressure cannot be applied under relatively high negative pressure conditions, such as -0.05 MPa, where good effects can be achieved with whole-body negative pressure. As shown in Figure 9, when the same pressure was applied under local negative pressure conditions, i.e., a local negative pressure of -0.05 MPa, severe mechanical damage occurred to the skin of mice.

[0115] Figure 10A shows a comparison of the white blood cell content in young mice in the control group, local negative pressure group, systemic negative pressure treatment group (-0.02 MPa), and systemic negative pressure treatment group (-0.05 MPa) on day 14. As shown in Figure 10A, on day 14 (7 days after 7 days of negative pressure treatment and 7 days of recovery), the blood test results showed that the white blood cell ratio in the local negative pressure group was significantly improved, further demonstrating that local negative pressure can induce inflammatory responses in the body.

[0116] (2) Blood test changes in young mice before and after negative pressure

[0117] Figures 10A-10D show comparisons of blood test values ​​on day 14 for young mice in the control group, local negative pressure group, systemic negative pressure treatment group (-0.02 MPa), and systemic negative pressure treatment group (-0.05 MPa). Figure 10A shows white blood cell content, Figure 10B shows red blood cell content, Figure 10C shows platelet content, and Figure 10D shows lymphocyte ratio.

[0118] As shown in Figures 10A-10D, young mice showed a decrease in white blood cells and an increase in lymphocyte ratio after systemic negative pressure. Compared with systemic negative pressure, the local negative pressure group showed a significant improvement in white blood cell and red blood cell ratios and an increase in platelets.

[0119] Example 5: Changes in human blood oxygen concentration in a negative pressure cabin

[0120] Various negative pressures were generated in the negative pressure cabin (Fig. 11A), and the blood oxygen concentration of the subjects was measured using a blood oxygen meter at each negative pressure. As shown in Fig. 11, there was no significant change in human blood oxygen concentration within the range of 0 MPa to -0.06 MPa (Fig. 11B).

[0121] Example 6: Removal of senescent cells by negative pressure

[0122] As shown in Figure 12 (Figure 12A-Figure 12D), aged mouse P2 bone marrow mesenchymal stem cells (BMMSCs), aged P25 umbilical cord mesenchymal stem cells (UMSCs) induced by artificial serial passage, and young cells were placed in a normal oxygen negative pressure incubator, treated for a while at -0.05 MPa, then removed and fixed. The aged cells were then stained and observed with β-galactosidase staining. Compared to young BMSCs / UMSCs, the number of β-Gal-positive (blue) cells in aged BMSCs / UMSCs gradually decreased under negative pressure treatment, while young BMSCs / UMSCs showed no significant change.

[0123] Example 7: Treatment of osteoporosis in aged mice with negative pressure

[0124] 1. Experimental Method

[0125] Eighteen-month-old C57BL6 mice were used as test animals. Experimental groups included young mice and a control group (aged mice without negative pressure treatment) (using the negative pressure cabin of the present invention, whole-body negative pressure treatment at -0.05 MPa was performed for 2 hours every day for a total of 6 weeks). After negative pressure treatment, the mice were anesthetized and euthanized. Peripheral blood mononuclear cells were isolated from the mice and subjected to β-Gal staining and P16 immunofluorescence staining. Femurs were scanned and analyzed using a Scanco μCT50 (Scanco Medical AG, Switzerland).

[0126] 2. Experimental Results

[0127] As shown in Figure 13 (Figures 13A-13K), negative pressure treatment can reduce the proportion of β-Gal and P16 positive cells in PBMCs, reverse the osteoporotic phenotype of aged mice, and improve each bone index.

[0128] Example 8: C. elegans experiments

[0129] 1. Experimental Method

[0130] (1) Nematode life span experiment

[0131] After synchronization, L4 stage N2 nematodes were transferred to fresh NGM plates containing OP50 and supplemented with 50 μM 5-fluoro-2'-deoxyuridine to prevent progeny growth. According to the experimental design, plates were placed in a negative pressure chamber and subjected to different pressures for 1 h each day. The number of surviving nematodes was monitored and recorded. Every 48 h, nematodes were transferred to new fresh NGM plates containing OP50 and monitored for subsequent statistical analysis. Nematodes were considered dead if they failed to respond to repeated platinum probes.

[0132] (2) Oil Red O staining

[0133] After synchronization, N2 nematodes were transferred to fresh NGM plates containing OP50 and placed in a negative pressure chamber for 6 days (1 hour per day) at different pressures according to the experimental design. After washing the nematodes twice with M9 solution, each group of nematodes was collected and fixed in 60% isopropyl alcohol for 30 minutes. After centrifugation, 60% Oil Red O staining solution was added to each sample and incubated overnight at room temperature. After staining, the samples were washed twice with M9 solution and observed for lipid droplets using an inverted microscope.

[0134] (3) Quantitative measurement of triglycerides

[0135] After synchronization, N2 nematodes were transferred to fresh NGM plates containing OP50 and placed in a negative pressure chamber for 6 days (1 h / day) at different pressures according to the experimental design. After washing the nematodes twice with M9 solution, each group of nematodes was collected in RIPA lysis solution, the tissue was homogenized, and the lysate was collected. The lysate was then centrifuged at 12,000 rpm for 30 minutes, and the protein concentration was measured by BCA assay. The triglyceride content of each group sample was quantified using a microplate reader according to the instructions in the triglyceride test box (Nanjing Jiancheng). The final results (triglyceride content / protein content) were then normalized to the total.

[0136] (4) Acute heat stress experiment

[0137] After synchronization, N2 nematodes were transferred to fresh NGM plates containing OP50 and placed in a negative pressure chamber for 6 days (1 hour per day) according to the experimental design. 20 nematodes from each group were randomly selected and placed on fresh NGM plates. They were then transferred to a 37°C incubator and incubated for 4 hours. After the heat treatment, they were left at room temperature for 12 hours and observed for statistical analysis of nematode survival rates.

[0138] 2. Experimental Results

[0139] (1) Changes in the life cycle of nematodes before and after negative pressure

[0140] The lifespan of nematodes was extended by exposure to pressures between -0.03 MPa and -0.05 MPa, with lifespan increasing by up to 26.31% at -0.05 MPa (Figure 14). Compared to the control group, aged nematodes (11 days) after negative pressure treatment had higher locomotor ability (Figure 15).

[0141] (2) Changes in fat reserve content before and after negative pressure treatment in nematodes

[0142] After negative pressure treatment, the accumulation of lipid droplets in the nematodes decreased. Under -0.05 MPa conditions, negative pressure also significantly reduced the triglyceride content of the nematodes (Figure 16). These results indicate that negative pressure treatment improves the hydrolysis of lipids in the nematodes and reduces the amount of lipids accumulated in the nematodes.

[0143] (3) Changes in the ability of nematodes to resist heat stress before and after negative pressure treatment

[0144] Compared to the control group, the nematodes treated with negative pressure were able to maintain a higher survival rate under acute heat stress (Figure 17), and the -0.05 MPa negative pressure group had the highest resistance effect to acute heat stress in the nematodes. As a result, negative pressure treatment improved the heat resistance ability of the nematodes and demonstrated a protective effect on the nematodes under acute heat stress conditions.

[0145] Example 9: Treatment of Nonalcoholic Fatty Liver Disease (NASH) with Negative Pressure

[0146] 1. Experimental Method

[0147] Mice with nonalcoholic steatohepatitis induced by a 22-week high-fat diet were subjected to negative pressure (-0.05 MPa, 2 hours daily) for 14 days. After 14 days, they were anesthetized with isoflurane and blood samples were collected for blood analysis. After blood collection, the mice were euthanized by cervical dislocation. Each organ, including the heart, liver, spleen, lungs, and kidneys, was isolated and fixed with paraformaldehyde. Then, the tissues were dehydrated, embedded in paraffin, and sliced ​​into 5-um-thick tissue sections. The liver was stained with HE, Oil Red, and Sirius Red for observation. Serum ALT and serum / tissue cholesterol levels were also measured.

[0148] 2. Experimental Results

[0149] HE staining of tissue sections showed that after negative pressure treatment, fatty vacuolar degeneration was significantly reduced, liver tissue was more orderly arranged, and inflammatory cell infiltration was significantly reduced (Figure 18). Oil red staining showed that after negative pressure treatment, fatty vacuoles were significantly reduced and oil red staining was reduced in the negative pressure group (Figure 19). Sirius red staining showed a slight improvement in liver fibrosis (Figure 20). NAS scoring showed a significant improvement in nonalcoholic fatty liver disease (Figure 21). Serum ALT measurement showed a significant decrease in ALT in the negative pressure group, with no statistically significant difference between the negative pressure group and the healthy group (Figure 22). Both plasma and tissue cholesterol content decreased, with statistically significant differences (Figure 23).

[0150] Example 10: Treatment of periodontitis in mice with negative pressure

[0151] 1. Experimental Method

[0152] A chronic periodontitis (CP) model was constructed, and the sutures were removed after two months. The experimental group (CP + negative pressure) was treated with negative pressure (-0.05 MPa) for 2 h / day for one month, after which the rats were anesthetized and euthanized, and the jawbone was isolated. The alveolar bone changes were analyzed by scanning using a Scanco μCT50 (Scanco Medical AG, Switzerland).

[0153] 2. Experimental Results

[0154] Compared with the control group (CP group), the bone defect area in the negative pressure group was significantly reduced (P>0.05) (Fig. 24).

[0155] Example 11: Treatment of hyperuricemia in mice with negative pressure

[0156] 1. Experimental Method

[0157] A chronic hyperuricemia mouse model was established by oral gavage of a combination of oteracil potassium and hypoxanthine once daily for 14 consecutive days.

[0158] Experimental groups were: (1) negative control group (Ctrl), (2) hyperuricemia mouse model group (UA), and (3) hyperuricemia mouse + negative pressure group (UA+NP). Hyperuricemia mice were subjected to negative pressure (-0.05 MPa) for 2 h daily while undergoing a dietary induction. After 14 days of negative pressure treatment, the activity of each group was monitored. After anesthesia, blood samples were collected for blood analysis. Neutrophils were isolated using mouse neutrophil isolation solution and subjected to flow lysis. After blood collection, the mice were euthanized by cervical dislocation. Then, tissues such as liver and kidney were isolated and fixed with paraformaldehyde. They were then dehydrated, paraffin-embedded, and frozen. Then, 5-μm-thick tissue sections were sliced ​​and examined for histological changes using HE staining, Masson staining, immunofluorescence, etc. The negative pressure treatment process was the same as above.

[0159] 2. Experimental Results

[0160] Compared with the negative control group, the hyperuricemia mice group had a decreased percentage of lymphocytes and an increased percentage of neutrophils. Negative pressure treatment could improve the lymphocyte ratio and decrease the neutrophil ratio in the blood of hyperuricemia mice. In addition, the hyperuricemia model did not significantly affect the blood red blood cell data. Furthermore, compared with the negative control group, the hyperuricemia mice group had an increased number of platelets, and negative pressure treatment could significantly decrease the platelet count in the hyperuricemia mice group (Figures 25A-25C).

[0161] Compared to the negative control group, the hyperuricemic mice lost weight and became less active. Negative pressure treatment can improve the weight of hyperuricemic mice (Figure 26). In addition, the activity of hyperuricemic mice decreased, and negative pressure can improve the activity of hyperuricemic mice (Figure 27).

[0162] Compared to the negative control group of mice, the hyperuricemic mice had increased blood uric acid levels. Negative pressure treatment can reduce the blood uric acid concentration of mice. BUN (urea nitrogen) is a protein metabolic product and an indicator of kidney function. Negative pressure treatment can reduce the BUN content in the blood of hyperuricemic mice. Serum creatinine (CRE) is a muscle metabolic product and an indicator of kidney function. Negative pressure can reduce the CRE content in the blood of hyperuricemic mice. Xanthine oxidase (XOD) is an indicator of liver function. Negative pressure can reduce the enzyme activity of XOD in the blood of hyperuricemic mice (Figure 28).

[0163] Compared with the negative control group mice, the livers of hyperuricemic mice exhibited vacuolar degeneration of hepatocytes and increased atypical nuclei. Negative pressure treatment significantly improved the histological changes in the livers of hyperuricemic mice. Compared with the negative control group mice, the kidney tissues of hyperuricemic mice exhibited glomerular atrophy and disorganized tubular structure. Negative pressure treatment significantly improved the histological changes in the kidneys of hyperuricemic mice (Figure 29). This result was further confirmed by Masson staining (Figure 30). Compared with the negative control group mice, the kidney tissues of hyperuricemic mice exhibited significant neutrophil inflammatory death, i.e., NETosis. Negative pressure treatment significantly reduced neutrophil inflammatory death in the kidneys of hyperuricemic mice (Figure 31).

[0164] Example 12: Relief of depression / anxiety in mice by negative pressure

[0165] 1. Experimental Method

[0166] Normal control C57BL / 6 mice and 10-12-week-old LPR mice (apoptosis gene Fas-deficient mice) before negative pressure treatment were subjected to anxiety / depression behavioral tests using the open field test, elevated plus maze test, and forced swim test. After negative pressure (-0.05 MPa) treatment, mice were subjected to negative pressure treatment for 2 h / day for 14 days, and behavioral changes were examined in the open field test, elevated plus maze test, and forced swim test together with normal control C57BL / 6 mice and untreated LPR mice. Data were analyzed and processed using Yoshikawa behavioral analysis software.

[0167] 2. Experimental Results

[0168] The anxiety level of mice can be assessed by their behavior in the open field test and the elevated plus maze test. In the forced swimming test, the cumulative time spent immobile indicates the depression level of mice. Compared with the control group, treatment with a whole-body -0.05 MPa negative pressure significantly improved the route taken by LPR mice in the central compartment of the open field (Figure 32). Furthermore, compared with the movement status before self-treatment, treatment with a whole-body -0.05 MPa negative pressure significantly improved the route taken by LPR mice in the central compartment of the open field (Figure 32). Treatment with a whole-body -0.05 MPa negative pressure significantly improved the movement time and number of entries in the open arms of the elevated plus maze (Figure 33). Furthermore, compared with the movement status before self-treatment, treatment with a whole-body -0.05 MPa negative pressure significantly improved the movement time and number of entries in the open arms of the elevated plus maze (Figures 34-35). In the forced swimming test, the immobility time of mice treated with whole-body negative pressure of -0.05 MPa was significantly reduced compared to untreated LPR mice (Figure 36). These experimental data demonstrate that the anxiety / depression levels of mice were reduced after negative pressure treatment.

[0169] Example 13: Treatment of enteritis in mice with negative pressure

[0170] 1. Experimental Method

[0171] Eight-week-old C57BL6 mice were subjected to negative pressure for three days, after which a 3% (w / v) DSS solution was added to their drinking water to establish a colitis mouse model. The colitis + negative pressure group mice were subjected to negative pressure (-0.05 MPa) for 2 h / day, while the colitis group and control group served as positive and negative controls, respectively. The DSS solution was replaced every two days. Ten days after model establishment, each group was anesthetized and euthanized, and colon samples were taken. The length of the colon from the cecum to the rectum was measured to assess the severity of colitis.

[0172] 2. Experimental Results

[0173] Compared to control mice, DSS treatment reduced the colon length, but after negative pressure treatment, the colon length of the mice tended to increase, indicating that negative pressure treatment alleviated DSS-induced colitis (Figure 37).

[0174] Example 14: Treatment of Alzheimer's disease (AD) in mice with negative pressure

[0175] 1. Experimental Method

[0176] Six 7-month-old APP / PS1 mice were randomly divided into two groups: the AD negative pressure group and the AD control group. The AD negative pressure group received whole-body negative pressure treatment at -0.05 MPa for 2 hours per day. The AD control group was untreated. Six 7-month-old wild-type C57BL6 mice were randomly divided into two groups: the WT negative pressure group and the WT control group. The WT negative pressure group received whole-body negative pressure treatment at -0.05 MPa for 2 hours per day. The WT control group was untreated. After 2 weeks of treatment, all mice were subjected to the Morris water maze test. The escape times of each group were analyzed and statistical analysis was performed to assess the learning and memory abilities of the mice.

[0177] 2. Experimental Results

[0178] As shown in Figure 38, after 2 weeks of -0.05 MPa negative pressure treatment, the Morris water maze escape time of APP / PS1 mice was significantly reduced, approaching that of wild-type mice, indicating that the learning and memory abilities of APP / PS1 mice were significantly restored.

[0179] Example 15: Treatment of atherosclerosis with negative pressure

[0180] 1. Experimental Method

[0181] ApoE- / - mice, a transgenic model of atherosclerosis, were subjected to continuous negative pressure (-0.05 MPa) for 2 h / day for 2 months, then anesthetized and euthanized. The aortic arches of the mice were isolated, dissected, fixed, and stained with Oil Red O.

[0182] 2. Experimental Results

[0183] As a result, as shown in Figures 39A-39C, the negative pressure group (Exp) showed a decrease in atherosclerotic plaque formation, and a decrease in blood triglycerides (TG) and total cholesterol (T-CHO).

[0184] The above description of the features of several embodiments or examples will enable those skilled in the art to better understand each aspect of the present invention. As will be appreciated by those skilled in the art, the present invention may readily be used as a basis for designing or modifying other processes and structures to carry out the same purposes and / or achieve the same advantages as the embodiments or examples presented herein. It should also be understood by those skilled in the art that such equivalent structures do not depart from the spirit and scope of the present invention, and that various changes, substitutions, and alterations can be made herein without departing from the spirit and scope of the present invention.

Claims

1. 1. Use of a device that provides whole-body negative pressure to a subject in the manufacture of equipment used in the prevention or treatment of disease, anti-aging, life extension, promotion of skin or bodily functions, and / or non-therapeutic cosmetic purposes.

2. 1. A method for treating disease, anti-aging, extending life span, promoting skin function, and / or non-therapeutic cosmetic purposes in a subject, comprising: The method comprising applying whole body negative pressure to the subject.

3. The disease comprises at least one selected from the group consisting of skin, liver, spleen, brain, kidney, and red blood cell-related diseases; Optionally, the disease comprises osteoporosis, metabolic inflammatory syndrome, heat stress injury, periodontitis, hyperuricemia, depression / anxiety, enteritis or Alzheimer's disease; Optionally, the heat stress injury is selected from acute heat stress injury; Optionally, the metabolic inflammatory syndrome is selected from obesity, fatty liver, or atherosclerosis; Optionally, the fatty liver comprises non-alcoholic fatty liver; Optionally, said enteritis is selected from colitis; Optionally, the anti-aging includes the prevention or treatment of aging; Optionally, the anti-aging comprises reducing the number of senescent cells in a tissue or organ; Optionally, the tissue or organ comprises at least one selected from the group consisting of liver, spleen, brain, and kidney; Optionally, the promotion of skin or bodily function includes promoting the growth of skin or its appendages; Optionally, the promotion of skin or bodily function includes promotion of athletic performance of the subject; 3. The use or method according to claim 1 or 2, optionally wherein the promotion of growth of the skin or its appendages comprises the promotion of hair regrowth or wound healing.

4. the systemic negative pressure is at least about 0.01 MPa negative relative to atmospheric pressure; Optionally, the systemic negative pressure is at least about 0.02 MPa negative relative to atmospheric pressure; Optionally, the systemic negative pressure is at least about 0.03 MPa negative relative to atmospheric pressure; Optionally, the systemic negative pressure is at least about 0.04 MPa negative relative to atmospheric pressure; Optionally, the systemic negative pressure is about 0.04 MPa to 0.06 MPa negative relative to atmospheric pressure; Optionally, the systemic negative pressure is between about 0.045 MPa and 0.055 MPa negative relative to atmospheric pressure; Optionally, the systemic negative pressure is about 0.05 MPa negative relative to atmospheric pressure; Optionally, applying whole-body negative pressure to the subject is performed by a device that applies whole-body negative pressure to the subject; The apparatus for applying whole body negative pressure to the subject comprises: a length of at least about 1 m, optionally between about 1 m and 2 m, optionally between about 1 m and 1.5 m; a width of at least about 1 m, optionally between about 1 m and 2 m, optionally between about 1 m and 1.5 m; a height of at least about 2 m, optionally about 2 m to 3 m, optionally about 2 m to 2.5 m; and / or Volume is at least about 1 m ３ , optionally at least about 2 m ３ , optionally about 2 m ３ ~3m ３ 4. The use or method according to any one of claims 1 to 3, characterized in that:

5. The oxygen ratio in the air under the whole-body negative pressure is equal to or greater than the oxygen ratio in atmospheric air, Optionally, the oxygen percentage of air at said whole body negative pressure is at least about 22%; Optionally, the oxygen percentage of air at said whole body negative pressure is at least about 25%; Optionally, the use or method according to any one of claims 1 to 4 is characterized in that the oxygen percentage in the air at said whole-body negative pressure is at least about 30%.

6. applying whole-body negative pressure to the subject simultaneously provides air to the subject's respiratory system having an oxygen percentage equal to or greater than the oxygen percentage of atmospheric air; Optionally, the oxygen percentage of the air provided is at least about 22%; Optionally, the oxygen percentage of the air provided is at least about 25%; 6. The use or method according to any one of claims 1 to 5, optionally characterized in that the oxygen percentage of the air provided is at least about 30%.

7. the device is a negative pressure cabin; Preferably, the negative pressure cabin comprises: A cabin body having a size capable of accommodating the entire object; a negative pressure device provided in the cabin body and capable of lowering the air pressure inside the cabin of the cabin body by at least about 0.01 MPa compared to the air pressure outside the cabin of the cabin body; an oxygen transport device provided on the cabin body or within a cabin of the cabin body, capable of increasing the ratio of oxygen to air in a space adjacent to the subject's respiratory system within the cabin of the cabin body to be equal to or greater than the ratio of oxygen to air outside the cabin of the cabin body; 7. The use according to any one of claims 1 to 6, characterized in that it comprises:

8. 1. A negative pressure cabin for providing negative pressure to a subject, comprising: A cabin body having a size capable of accommodating the entire object; a negative pressure device provided in the cabin body and capable of lowering the air pressure inside the cabin of the cabin body by at least about 0.01 MPa compared to the air pressure outside the cabin of the cabin body; an oxygen transport device provided on the cabin body or within a cabin of the cabin body, capable of increasing the ratio of oxygen to air in a space adjacent to the subject's respiratory system within the cabin of the cabin body to equal or exceed the ratio of oxygen to air outside the cabin of the cabin body; A negative pressure cabin comprising:

9. The negative pressure device can make the air pressure inside the cabin of the cabin body lower than the air pressure outside the cabin of the cabin body, the systemic negative pressure is at least about 0.02 MPa negative relative to atmospheric pressure; Optionally, a negative pressure of at least about 0.03 MPa; Optionally, a negative pressure of at least about 0.04 MPa; Optionally, the negative pressure device can reduce the air pressure inside the cabin of the cabin body by approximately 0.04 MPa to 0.06 MPa below the air pressure outside the cabin of the cabin body; optionally, by about 0.045 MPa to 0.055 MPa; optionally, by about 0.05 MPa; and / or the oxygen delivery device is capable of providing an oxygen fraction in the cabin space adjacent to the subject's respiratory system of at least 22%, optionally at least 25%, optionally at least 30%; Optionally, the length of the cabin body is at least about 1 m, optionally between about 1 m and 2 m, optionally between about 1 m and 1.5 m; the width of the cabin body is at least about 1 m, optionally about 1 m to 2 m, optionally about 1 m to 1.5 m; the height of the cabin body is at least about 2 m, optionally about 2 m to 3 m, optionally about 2 m to 2.5 m; and / or The volume is at least about 1 m ３ , optionally at least about 2 m ３ , optionally about 2 m ３ ~3m ３ and Optionally, the negative pressure cabin comprises: an oxygen supply device connected to the oxygen transport device and in pneumatic communication with the cabin of the cabin body via the oxygen transport device; and / or an oxygen delivery port connected to the oxygen delivery device and adapted to be connected to the subject and used to provide oxygen to the subject; Optionally, the negative pressure cabin comprises: a negative pressure destruction device that is provided in the cabin body, the inside of the cabin and the outside of the cabin being air-pressure isolated from each other under a first state of the negative pressure destruction device, and the inside of the cabin and the outside of the cabin being air-pressure communicated with each other under a second state of the negative pressure destruction device; A see-through structure provided on the cabin body, which can make the inside of the cabin visible from the outside of the cabin and / or can make the outside of the cabin visible from the inside of the cabin; a display device provided in the cabin body; a lighting device provided in the cabin body and directed into the cabin; and / or 9. The negative pressure cabin according to claim 8, further comprising a control device provided in the cabin body for controlling at least one of the negative pressure device and the oxygen transport device.

10. 10. Use of a negative pressure cabin according to claim 8 or 9 in the manufacture of equipment for use in the prevention or treatment of diseases, life extension, anti-aging and / or promotion of skin or body functions or for non-therapeutic cosmetic purposes, Optionally, the disease is selected from skin, liver, spleen, brain, kidney and / or red blood cell related diseases; Optionally, the disease comprises osteoporosis, metabolic inflammatory syndrome, heat stress injury, periodontitis, hyperuricemia, depression / anxiety, enteritis or Alzheimer's disease; Optionally, the heat stress injury is selected from acute heat stress injury; Optionally, the metabolic inflammatory syndrome is selected from obesity, fatty liver, or atherosclerosis; Optionally, the fatty liver comprises non-alcoholic fatty liver; Optionally, the anti-aging includes the prevention or treatment of aging; Optionally, the anti-aging comprises reducing the number of senescent cells in a tissue or organ; Optionally, the tissue or organ comprises at least one selected from the group consisting of liver, spleen, brain, and kidney; Optionally, the promotion of skin or bodily function includes promoting the growth of skin or its appendages; Optionally, the promotion of skin or bodily function includes promotion of athletic performance of the subject; Optionally, the promotion of skin function includes promoting hair regrowth or wound healing.

Images